Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity?
The current preclinical study demonstrated that chronic treatment with CAB improves obesity-associated metabolic disorders such as dyslipidemia and hyperinsulinemia, by regulating the expression of lipid accumulation markers and reducing skeletal muscle ectopic lipid accumulation.
Authors
- Laura Rinaldi (ORCID: https://orcid.org/0000-0002-0975-2052)
- Roberta Patalano (ORCID: https://orcid.org/0000-0002-3639-7287)
- Antonio Feliciello (ORCID: https://orcid.org/0000-0002-7932-2170)
- Raffaella Crescenzo (ORCID: https://orcid.org/0000-0001-6138-6961)
- Mariarosaria Negri
- Davide Menafra (ORCID: https://orcid.org/0000-0002-4403-6801)
- Guendalina Del Vecchio
- Renata S. Auriemma (ORCID: https://orcid.org/0000-0002-1494-3419)
- Rosario Pivonello (ORCID: https://orcid.org/0000-0002-9632-1348)
- Feliciana Amatrudo
- Donatella Paola Provvisiero
- Annamaria Colao
- Claudia Pivonello
- Maria Anna Marciano
Institutions
- Federico II University Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.biopha.2025.118243
- Primary Topic
- Adipose Tissue and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Ministero dell'Università e della Ricerca